TY - JOUR
T1 - Analysis of angiogenesis related factors in glioblastoma, peritumoral tissue and their derived cancer stem cells
AU - D'Alessio, Alessio
AU - Proietti, Gabriella
AU - Lama, Gina
AU - Biamonte, Filippo
AU - Lauriola, Libero
AU - Moscato, Umberto
AU - Vescovi, Angelo
AU - Mangiola, Annunziato
AU - Angelucci, Cristiana
AU - Sica, Gigliola
N1 - Funding Information:
We are grateful to Dr. Anna Colabianchi for technical support in immunoblotting analysis of HIFs. This work was supported from Italian Ministry for Education, University and Research (MIUR, 2010), FIRB Project RBAP10KJC5 and from the AIRC grant #14368 IG 2013.
PY - 2016
Y1 - 2016
N2 - The formation of new blood vessels represents a crucial event under both physiological and pathological circumstances. In this study, we evaluated by immunohistochemistry, and/or Western blotting and/or quantitative real time-PCR the expression of HIF1a, HIF2a, VEGF, VEGFR1 and VEGFR2 in surgical glioblastoma multiforme (GBM) and peritumoral tissue samples obtained from 50 patients as well as in cancer stem cells (CSCs) isolated from GBM (GCSCs) and peritumoral tissue (PCSCs) of 5 patients. We also investigated the contribution of both GCSCs and PCSCs on the behavior of endothelial cells (ECs) in vitro. Immunohistochemistry demonstrated the expression of angiogenesis markers in both GBM and peritumoral tissue. In addition, in vitro tube formation assay indicated that both GCSCs and PCSCs stimulate EC proliferation as well as tube-like vessel formation. An increased migration aptitude was mainly observed when ECs were cultured in the presence of GCSCs rather than in the presence of PCSCs. These findings suggest that relevant neoangiogenetic events may occur in GBM. In particular, VEGF/VEGFR co-expression in PCSCs leads to hypothesize the involvement of an autocrine signaling. Moreover, our results suggest that both GCSCs and PCSCs own the skill of activating the "angiogenic switch" and the capability of modulating EC behavior, indicating that both cell types are either responsive to angiogenic stimuli or able to trigger angiogenic response. Together with our previous findings, this study adds a further piece to the challenging puzzle of the characterization of peritumoral tissue and of the definition of its real role in GBM pathophysiology.
AB - The formation of new blood vessels represents a crucial event under both physiological and pathological circumstances. In this study, we evaluated by immunohistochemistry, and/or Western blotting and/or quantitative real time-PCR the expression of HIF1a, HIF2a, VEGF, VEGFR1 and VEGFR2 in surgical glioblastoma multiforme (GBM) and peritumoral tissue samples obtained from 50 patients as well as in cancer stem cells (CSCs) isolated from GBM (GCSCs) and peritumoral tissue (PCSCs) of 5 patients. We also investigated the contribution of both GCSCs and PCSCs on the behavior of endothelial cells (ECs) in vitro. Immunohistochemistry demonstrated the expression of angiogenesis markers in both GBM and peritumoral tissue. In addition, in vitro tube formation assay indicated that both GCSCs and PCSCs stimulate EC proliferation as well as tube-like vessel formation. An increased migration aptitude was mainly observed when ECs were cultured in the presence of GCSCs rather than in the presence of PCSCs. These findings suggest that relevant neoangiogenetic events may occur in GBM. In particular, VEGF/VEGFR co-expression in PCSCs leads to hypothesize the involvement of an autocrine signaling. Moreover, our results suggest that both GCSCs and PCSCs own the skill of activating the "angiogenic switch" and the capability of modulating EC behavior, indicating that both cell types are either responsive to angiogenic stimuli or able to trigger angiogenic response. Together with our previous findings, this study adds a further piece to the challenging puzzle of the characterization of peritumoral tissue and of the definition of its real role in GBM pathophysiology.
KW - Angiogenesis
KW - Cancer stem cells
KW - Glioblastoma
KW - Hypoxia
KW - Peritumoral tissue
UR - http://www.scopus.com/inward/record.url?scp=84999014755&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84999014755&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.12398
DO - 10.18632/oncotarget.12398
M3 - Article
C2 - 27705944
AN - SCOPUS:84999014755
VL - 7
SP - 78541
EP - 78556
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 48
ER -